Quantinno Capital Management LP Buys 8,172 Shares of Bruker Co. (NASDAQ:BRKR)

Quantinno Capital Management LP grew its holdings in shares of Bruker Co. (NASDAQ:BRKR - Free Report) by 210.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 12,057 shares of the medical research company's stock after acquiring an additional 8,172 shares during the quarter. Quantinno Capital Management LP's holdings in Bruker were worth $707,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Malaga Cove Capital LLC raised its position in Bruker by 22.0% in the 4th quarter. Malaga Cove Capital LLC now owns 14,526 shares of the medical research company's stock worth $852,000 after purchasing an additional 2,615 shares during the period. Nomura Holdings Inc. raised its position in Bruker by 109.8% in the 4th quarter. Nomura Holdings Inc. now owns 14,684 shares of the medical research company's stock worth $861,000 after purchasing an additional 7,684 shares during the period. NorthRock Partners LLC purchased a new position in Bruker in the 4th quarter worth $211,000. Nuveen Asset Management LLC grew its holdings in Bruker by 35.4% in the 4th quarter. Nuveen Asset Management LLC now owns 1,217,940 shares of the medical research company's stock worth $71,396,000 after acquiring an additional 318,630 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp grew its holdings in Bruker by 21.7% in the 4th quarter. OMERS ADMINISTRATION Corp now owns 184,200 shares of the medical research company's stock worth $10,798,000 after acquiring an additional 32,800 shares during the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker Price Performance

Shares of NASDAQ:BRKR traded down $0.10 on Wednesday, reaching $37.06. The company's stock had a trading volume of 518,658 shares, compared to its average volume of 2,157,463. The company has a 50-day simple moving average of $39.05 and a 200 day simple moving average of $49.36. Bruker Co. has a 52-week low of $34.10 and a 52-week high of $74.32. The company has a market cap of $5.62 billion, a P/E ratio of 48.85, a PEG ratio of 2.16 and a beta of 1.23. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60.

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The medical research company reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. The company had revenue of $801.40 million for the quarter, compared to analyst estimates of $763.83 million. During the same quarter in the prior year, the firm posted $0.53 EPS. Bruker's quarterly revenue was up 11.0% compared to the same quarter last year. As a group, equities research analysts anticipate that Bruker Co. will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Monday, June 16th will be paid a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, June 16th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.54%. Bruker's dividend payout ratio is presently 38.46%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Stifel Nicolaus cut their target price on shares of Bruker from $57.00 to $48.00 and set a "hold" rating on the stock in a research note on Thursday, May 8th. The Goldman Sachs Group dropped their target price on shares of Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a research note on Thursday, May 8th. Citigroup cut shares of Bruker from a "strong-buy" rating to a "hold" rating and decreased their price objective for the company from $50.00 to $40.00 in a report on Thursday, May 22nd. UBS Group reduced their target price on shares of Bruker from $57.00 to $45.00 and set a "neutral" rating for the company in a report on Thursday, May 8th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Bruker in a report on Monday, February 24th. Six equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $59.10.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.